Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Merger or Acquisition (December 2020)
17 slides from Telix Pharmaceuticals's merger presentation, Dec 1, 2020
Slide 1: Targeted Radiation for Cell Therapies: TheraPharm GmbH Acquisition
Targeted Radiation for Cell Therapies TheraPharm GmbH Acquisition Telix Pharmaceuticals Limited 1st December 2020
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (“Telix”) in any jurisdiction, including the United States. No representation or warranty, express or implie
Slide 3: Executive summary
Executive summary • The TheraPharm GmbH acquisition is a strategically consistent and highly additive transaction • Key asset is a radiolabeled monoclonal antibody that “hits” a specific target called “CD66”, expressed on the surface of certain types of white blood cells • Transaction structure: ✓ €
Slide 4: Who is TheraPharm?
Who is TheraPharm? • Development subsidiary of Scintec Diagnostics GmbH • Privately held Swiss (Zug)-headquartered company • Founded by Dr. Klaus Bosslet and Dr. Silke Thomsen, highly experienced pharma execs with a strong background in drug development • Technology originated from Behringwerke AG •
Slide 5: A picture says a thousand words
A picture says a thousand words … Telix : 2015 – Telix + TheraPharm : 2020 – 68Ga-PSMA for imaging cancer cells (1) 111In/99Tc-CD66 for imaging immune cells These scans show the These scans show the location of prostate location of neutrophils, cancer cells that have a type of granulocyte spread thr
Slide 6: What is Cluster of Differentiation 66 or CD66?
What is “Cluster of Differentiation 66” or “CD66” ? The heart of TheraPharm’s technology platform is a monoclonal antibody that hits a target called CD66, expressed uniquely on certain types of leukocytes (white blood cells). Telix is interested in imaging – and in some cases treating – three differ
Slide 7: The missing MTR puzzle piece
The missing MTR “puzzle piece” Integration with XRT Radiation Oncology More than just imaging… Optimal radiation delivery will Telix’s imaging product portfolio ultimately be a combination of drives patient planning, selection internal and external radiation and treatment monitoring across all thera
Slide 8: Diagnostic imaging product – 99mTc-besilesomab (Scintimun)
Diagnostic imaging product – 99mTc-besilesomab (Scintimun®) • Technetium-99m (99mTc) labelled besilesomab (anti-CD66 antibody) • Approved product in Europe, currently sold and marketed by Curium Pharma • Indicated for locating areas of infection or inflammation in patients with suspected bone infect
Slide 9: Therapeutic product – 90Y-besilesomab (90Y-anti-CD66-MTR)
Therapeutic product – 90Y-besilesomab (90Y-anti-CD66-MTR) • Yttrium-90 (90Y) labelled besilesomab, providing therapeutic MTR directed Bone marrow containing tumor towards cells expressing CD66 (90Y-anti-CD66-MTR) cells pre 90Y-anti-CD66-MTR: • TheraPharm has developed 90Y-anti-CD66-MTR for the initi
Slide 10: Compelling clinical value proposition for 90Y-anti-CD66-MTR
Compelling clinical value proposition for 90Y-anti-CD66-MTR 90Y-anti-CD66-MTR is potentially an ideal BMC agent for HSCT • Significantly reduced toxicity Compared with existing chemotherapeutic • Improved tolerability approaches (1, 2) • Significantly reduced hospitalisation time ✓ Suitable for outp
Slide 11: Under-served field with limited new innovation
Under-served field with limited new innovation • Standard of Care (HSCT) ✓ Chemotherapeutic approaches (e.g. Melphalan +) are highly toxic ✓ Many patients are ineligible, intensive hospitalization, limits wider use of HSCT approaches relative to risk-benefit profile • Actinium Pharmaceuticals, Inc.
Slide 12: 90Y-anti-CD66-MTR interfaces oncology, immunology, rheumatology
90Y-anti-CD66-MTR interfaces oncology, immunology, rheumatology Hematopoietic Stem Cell Transplant (HSCT) indications that may benefit from 90Y-anti-CD66-MTR bone marrow conditioning (BMC) Oncology Indications Non-oncology Indications • Acute myeloid leukemia (AML) • SALA • Acute lymphoblastic leuke
Slide 13: 90Y-anti-CD66-MTR is currently under investigation for SALA
90Y-anti-CD66-MTR is currently under investigation for SALA (1) • Phase I study of Targeted Radiotherapy for AL Amyloidosis (TRALA Study) (2) • Disease: Systemic Amyloid Light-Chain Amyloidosis (SALA) Faulty plasma cells ✓ Rare disease with a poor prognosis (median survival ~11 months if untreated)
Slide 14: TheraPharm acquisition (share purchase) summary
TheraPharm acquisition (share purchase) summary • Upfront payment: EUR €10.2M (~AUD $16.5M) upfront payment comprising: ✓ EUR €10.0M (~AUD $16.2M) in Telix shares based on 10-day VWAP at completion ✓ EUR €0.2M (~AUD $0.3M) completion cash payment • First earn-out component: EUR €5.0M (~AUD $8.1M) ca
Slide 15: Operational and budgetary impact
Operational and budgetary impact • Phase I ‘TRALA’ clinical study of 90Y-anti-CD66-MTR in patients with SALA is expected to report preliminary results mid-December 2020 (1) • 90Y-anti-CD66-MTR has potential for fast-track development for treatment of SALA ✓ Rare disease with a very poor prognosis ✓
Slide 16: Summary
Summary • Extends Telix’s MTR capabilities into a major new application space • Single asset opens new opportunities in hematologic oncology, HSCT transplant medicine and a variety of high-value rare diseases • Diagnostic product EMA approved and revenue generating, with significant potential for ex
Slide 17: telixpharma.com
Precision Oncology. See it. Treat it. , | telixpharma.com
Telix Pharmaceuticals — Merger or Acquisition (December 2020) on 6ix